作者: Christopher G. Azzoli
DOI: 10.1245/S10434-015-4704-Z
关键词:
摘要: Over a decade since the discovery of EGFR mutation, and 6 years prospective clinical trial data proved that routine molecular pathology tests improve survival in stage IV lung cancer, there is still debate whether to test patients with earlier stages disease (stage I–III). As discoveries targeted drugs for accelerate—prompting testing ALK, ROS1, RET, BRAF V600E, HER2, among others—there an argument all cancers should be genotyped purpose classification, regardless disease. The counterargument because have only been validated use disease, these need conducted at time recurrence. This review will describe current, practical applications early focusing on immediate diagnostic, prognostic, therapeutic implications individual patient management. Meanwhile, large-scale trials are underway as adjuvant therapies